Related Experiment Video

Updated: Jan 23, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K

Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors

Shalom Z Frager1, Abhay Dhand2, Alan Gass3

  • 1From the Department of Medicine, Division of Gastroenterology and Hepatobiliary Disease.

Cardiology in Review
|June 11, 2019
PubMed

Insights

Transplanting organs from hepatitis C virus (HCV) positive donors to negative recipients expands the donor pool. While outcomes are acceptable, long-term risks of HCV transmission and treatment failure require further study.

Area of Science:

  • Transplantation medicine
  • Infectious disease

Background:

  • Transplant wait-list mortality is a significant issue, driving strategies to expand the donor pool.
  • Direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) have revolutionized treatment.
  • The use of organs from HCV-viremic donors to HCV-negative recipients is a novel strategy to increase organ availability.

Purpose of the Study:

  • To review the existing literature on the risks and benefits of transplanting organs from HCV-viremic donors to HCV-negative recipients.
  • To present institutional data on this specific patient population.
  • To address uncertainties regarding long-term outcomes and sustained virologic response.

Main Methods:

  • Literature review of studies reporting outcomes of heart transplantation from HCV-viremic donors to HCV-negative recipients.
  • Analysis of data from a specific institution concerning this patient cohort.

Main Results:

  • Multiple centers report acceptable post-transplant outcomes for heart transplantation using organs from HCV-viremic donors.
  • Data from the institution supports the feasibility of this approach.
  • Areas of uncertainty persist regarding long-term risks and treatment efficacy.

Conclusions:

  • Transplantation of organs from HCV-viremic donors to HCV-negative recipients is a viable strategy to expand the donor pool.
  • Careful consideration of potential long-term risks, including sustained virologic response, is essential.
  • Further research and long-term follow-up are necessary to fully understand the implications of this practice.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Concept Videos

What are Viruses?00:50

What are Viruses?

Overview
127.9K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
542
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
305